Survey
Quarterly Survey: Type 2 Diabetes GLP-1 Treatments including LLY's Mounjaro and NVO's Ozempic January 2024
Ticker(s): LLY, NVO, AZN, VKTXThe survey results include 20 Endocrinologists.
How many patients with Type 2 Diabetes do you have under your care?
Are you currently prescribing or managing GLP-1 treatments for patients with Diabetes?
How many of your patients are eligible for a GLP-1 treatment?
What is the percentage breakdown of your patients currently on the following GLP-1 treatments?
- Mounjaro (tirzepatide):
- Ozempic (semaglutide):
- Rybelsus (semaglutide):
- Victoza, Saxenda (Liraglutide):
- Trulicity (dulaglutide):
- Bydureon BCise (exenatide extended-release):
- Byetta (exenatide)
- Other:
What do you expect the percentage breakdown of GLP-1 treatments among your patients to be 1 year from now?
- Mounjaro (tirzepatide):
- Ozempic (semaglutide):
- Rybelsus (semaglutide):
- Victoza, Saxenda (Liraglutide):
- Trulicity (dulaglutide):
- Bydureon BCise (exenatide extended-release):
- Byetta (exenatide)
- Other:
Which of the following GLP-1 treatments has the most promise?
- Mounjaro (tirzepatide):
- Ozempic (semaglutide):
- Rybelsus (semaglutide):
- Victoza, Saxenda (Liraglutide):
- Trulicity (dulaglutide):
- Bydureon BCise (exenatide extended-release):
- Byetta (exenatide)
- Other:
Why is that?
How many patients have started Ozempic (semaglutide) in the past 30 days?
How many patients have discontinued Ozempic (semaglutide)in the past 30 days?
How many patients have started Mounjaro (tirzepatide) in the past 30 days?
How many patients have discontinued Mounjaro (tirzepatide) in the past 30 days?
Please elaborate on your view of Mounjaro (tirzepatide).
How would you rate Mounjaro (tirzepatide) on the following (where 1 is low and 5 is high)?
- Safety
- Efficacy
- Payor Access
Do the side effects of Mounjaro (tirzepatide) limit your prescribing rate?
Which side effects limit your prescribing of Mounjaro (tirzepatide)?
On average, what percentage of your patients prescribed with GLP-1 treatments discontinue the treatment within the first year?
What are the most common reasons patients cite for discontinuing GLP-1 treatments within the first year?
How does the dropout rate influence your approach to recommending or prescribing GLP-1 treatments in your current patient population?
What changes, if any, have you noticed with payor reimbursement and insurance for diabetes and weight loss treatments?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
